I need rephrasing for the following paragraph please:In the new booming industrial world, it has become common to learn about new scientific fields that either come from sub-science discipline, or from combining two or more different scientific disciplines forming a new field that studies the relationships between the primary sciences.For example: under the big umbrella of Biological Sciences, we find various sub-sciences such as biotechnology, molecular biology, microbiology… etc. while a combination of biology and physics would be biophysics, or a combination of biology, geology, and chemistry would be biogeochemistry. Some of the disciplines have lost their scientific scopes and scales, as for non-specialists it is hard to distinguish between the too many interdisciplinary scientific terms. Many of the terms are being mixed, and sometimes different terms and definitions are being used as synonymous, which leads to a serious misunderstanding of these terms and definitions.From this point the necessity rose to have a closer look on some of the scientific disciplines which will be discussed later throughout this Meta research. It is very important to sit a base of understanding for which terms will be used and analyzed later on.This research paper is meant to give a clear view on a new emerging scientific discipline: Biomimetics and make a distinct differentiation with Bio-inspiration in general, as well as their specific functions and process. To be able to do so, we will have closer look at the component of those disciplines, their methodology and final products.The research takes case studies into consideration, where both concepts will be analyzed throughout their applications.This study meant to link both aspects together, investigate the current situation, and finally search for further niche for better use of both terms and their meaning.

in the present scenario of booming industrial world, it has become necessary to learn about newscientific fields that either come from sub science desciplines, or from combining variousdifferent…

"Looking for a Similar Assignment? Get Expert Help at an Amazing Discount!"

i need short answer!!!!!

1. What part of a motor neuron is found at a neuromuscular junction?
2. What neurotransmitter is released at a neuromuscular junction?
3. What is a synaptic cleft?
4. Which cell of a NMJ has receptors for the neurotransmitter?
5. At a neuromuscular junction, what does the muscle cell produce after the neurotransmitter binds the receptors for ACh?
6. Describe the basic functions/events at a neuromuscular junction?
7. What two substances are needed for actin and myosin filaments to interact and produce contraction?
8. What releases Ca+ when the muscle cell is stimulated?
9. What is the charge inside and outside a muscle cell at rest?
10. What is the ion found in abundance outside the cell at rest?
11. What is the ion found in abundance inside the cell at rest?
12. Be able to understand what’s happening during depolarization, propagation, repolarization and the refractory period when an action potential is generated in a muscle cell.
13. Explain how myosin interacts (the sliding filament theory) with actin to produce contraction.
14. What is a tendon? Aponeurosis?
15. What is a motor unit?
16. What would produce a stronger contraction, stimulating a few motor units or stimulating many motor units?
17. Be able to identify the muscles listed in your lab exercises packet from written descriptions of their shape and location OR from diagrams
18. Be able to recognize examples of antagonists and synergists from the muscles in lab
19. Describe how skeletal muscle/muscle fibers is/are innervated.
20. What are z-discs and how do they relate to actin filaments?
21. How are the CT layers of skeletal muscles related to tendons and connecting muscle to bone/periosteum?
22. Describe he gross anatomy of skeletal muscle (the 3 CT layers, fascicles, presence of blood vessels and nerves).

"Looking for a Similar Assignment? Get Expert Help at an Amazing Discount!"

i need solution plshttp://www.deloitte.com/assets/Dcom-UnitedStates/Local%20Assets/Documents/us_10_3c_restructing_costs_080610.pdfCase 10-3Restructuring CostsPharma Co. is a U.S. subsidiary of a U.K. entity that prepares its financial statements in accordance with (1) U.S. GAAP for reporting to its U.S.-based lender and (2) IFRSs in reporting to its parent. Pharma Co. is in the process of restructuring a business line. As part of the restructuring, Pharma Co. is considering the relocation of a manufacturing operation from its present location to a new facility in a different geographic area. The relocation plan would include terminating certain employees.IAS 37 includes guidance for accounting for restructuring costs in accordance with IFRSs. Paragraph 10 of IAS 37 defines restructuring as follows:[A] programme that is planned and controlled by management, and materially changes either:a.the scope of a business undertaken by an entity; orb.the manner in which that business is conducted.Under IFRSs, emphasis is placed on the recognition of the costs of the exit plan as a whole, whereas under ASC 420-10 (Statement 146) in U.S. GAAP, each type of cost should be examined individually to determine when it should be accrued. As a result, there may be differences in timing of recognition of restructuring costs under IFRSs and U.S. GAAP.Pharma Co. has taken the following actions:1.On December 15, 2008, Pharma Co. issued a press release announcing its intentions to terminate the lease of the old facility. The press release is included as Appendix A. Assume the terms of the lease are such that Pharma Co. accounts for the lease as an operating lease. Further, the lease agreement stipulates that written notice is required for early termination.2.On December 27, 2008, Pharma Co. management communicated the main features of a one-time, nonvoluntary termination plan to its employees. The communication to the employees is included as Appendix B.3.Pharma Co. will incur a relocation cost of $500,000 and staff training cost of $1.5 million. Further, Pharma Co. has entered into irrevocable contracts with certain other relevant parties to affect the restructuring plan over the following 18 months.4.The cost to dismantle the existing manufacturing operation is estimated to be $1 million. In the jurisdiction in which Pharma Co. operates its current facility, there is no legal obligation for dismantling plants when abandoned. Pharma Co. has not historically dismantled its plants when abandoned but decided to make an exception.Copyright 2009 Deloitte Development LLCAll Rights Reserved.Case 10-3: Restructuring Costs Page 2The company has, in a press release, stated its intention to dismantle the existing operation. The costs to reassemble the operation in the new facility have not yet been finalized.Required:•In reporting to its U.K. parent under IFRSs, how should Pharma Co. account for the above restructuring program for the year ended December 31, 2008?•In reporting to its U.S.-based lender in accordance with U.S. GAAP, how should Pharma Co. account for the restructuring program for the year ended December 31, 2008?Copyright 2009 Deloitte Development LLCAll Rights Reserved.Case 10-3: Restructuring Costs Page 3APPENDIX APress ReleasePharma Co. Announces Early Lease TerminationTulsa – 12/15/2008 – Pharma Co., a leading pharmaceutical developer, today announced its plan to terminate the lease on its Plant A facility located in Bellvue, Oklahoma, as part of its management restructuring and cost-cutting measures. Earlier today, Pharma Co. entered into an oral agreement with the lessor to terminate the lease. The lease termination fee is $1.3 million.The lease agreement was originally entered into in February 2002 and provided for Pharma Co. to occupy 100 percent of a 146,300-square-foot building in the Bellvue area of Tulsa with a term of 10 years.Pharma Co. plans to vacate the Plant A facility on January 31, 2009, at which time it will sign the lease termination agreement. Copyright 2009 Deloitte Development LLCAll Rights Reserved.Case 10-3: Restructuring Costs Page 4Copyright 2009 Deloitte Development LLCAll Rights Reserved.APPENDIX BInter-Office MemorandumTo: All Employees of Pharma Co.From: Gregory Seagate, Director, Human Resources**For internal distribution only**December 27, 2008Today, the leaders of Pharma Co. have determined to discontinue the research and development of our line of Live4mor drugs, which was initially publicized as the company’s response to the market place’s demand for more drugs embodying the latest in anti-aging drug technologies.As a result of management’s decision to eliminate its activities pertaining to theLiv4mor line of drugs, we will be implementing a one-time nonvoluntary termination plan to reduce our workforce. Although management has not yet identified the specific employees to be terminated, the current restructuring plan involves a reduction of approximately 120 employees, which represents 10 percent of our workforce. The workforce reduction is expected to be completed by January 31, 2009, and is expected to cost approximately $2 million.Our president and chief executive officer, Catherine Smith, made the following remarks this morning, “The restructuring plan that we are announcing today is a painful but unavoidable action given the change in the company’s priorities and the competition in the market place. While we are still a financially strong company, the restructuring plan will better prepare us for the future.”Decisions will be communicated as soon as possible. In the meantime, please feel free to contact me with any questions or concerns.Gregory

"Looking for a Similar Assignment? Get Expert Help at an Amazing Discount!"

I need some assistance with these assignment. 1:what is occupational health psychology and what can it offer organizations and employees Thank you in advance for the help! The emerging business environment calls for new approach to employee welfare and wellbeing. The field has gained significance over the years to include research works and introduce new concepts for emotional and physical wellbeing of workers at workplace. The subsequent paragraphs explore the concept of OHP and its contribution to organizations and employees.

Occupational health psychology (OHP) defines the health risks and hazards to which employees are exposed at workplace. OHP “concerns the application of psychology to improving the quality of work life, and to protecting and promoting the safety, health, and well-being of workers” (CDC, 2012). The concept of health protection relates to the intervention of occupational health psychologists in regulating the exposure of workers to risks and hazards at workplace. The basic function of the health psychologists involves the creation of safe and amiable workplace through adequate knowledge of how work conditions can impact employee health, wellbeing, and morale. The existing work conditions and workplace environment has the potential of causing psychological, social or physical harm to employees. Leka and Houdmont (2010) in their works on OHP reflect that psychological risks at workplace can stem from feelings of job insecurity, ageing workforce, long work hours, stressful work conditions and poor work-life balance. These have the potential to impact the psychological wellbeing of the employees over a period of time. Recent studies in this context have also revealed that psychological risks at workplace are on the rise (Leka and Houdmont, 2010. Bevan, 2010). These studies indicate that workplace stress and chronic health issues can prove to be serious barriers to improved performance and productivity.

"Looking for a Similar Assignment? Get Expert Help at an Amazing Discount!"